From Open Secrets:

In politics, 2015 may be remembered as the year of Trump and Carson, Clinton and Sanders. In the business world, especially in the health care industry, it may be remembered as the year of the merger.

But many politicians aren’t at all happy about the latest such effort: New York-based Pfizer‘s plan, announced Monday, to join forces with Allergan in a mammoth $160 billion deal.

What’s making them queasy: Allergan, headquartered in Dublin, will actually acquire the larger Pfizer, allowing Pfizer – as the combined company will be called – to pay much lower taxes while changing little about how it operates in the United States. Pfizer’s effective U.S. tax rate is currently about 25 percent. After the merger, it would plummet to about 17 or 18 percent, with the money going to the Republic of Ireland. One of the largest drugmakers worldwide with household-name products like Viagra and Lipitor, Pfizer tried to implement a similar strategy, known as an inversion, last year by taking over London-based AstraZeneca, but the companies failed to strike a deal.

Pfizer seems unlikely to bow to grumbling lawmakers – and is sure to rev up its lobbying machine as lawmakers and regulators scrutinize the megadeal, which would create the biggest drug producer in the world if successful.

There’s little dispute that Pfizer packs a lot of lobbying muscle. Take its approach to the Affordable Care Act. During 2009, when the debate over passing Obamacare was at a fever pitch, Pfizer spent $25.8 million

Continue Reading